March 4, 2019
Feraccru non-inferior to IV iron therapy in treating iron deficiency anaemia.
Shield Therapeutics got positive results from the AEGIS-H2H clinical trial which compared Feraccru (ferric maltol) to Ferinject (ferric carboxymaltose (FCM)), as Feraccru has demonstrated it is non-inferior to IV iron therapy in treating iron deficiency anaemia.